Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Policy / Pricing
  • How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market
  • Policy / Pricing

How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market

KFF Medicare

The private plans that offer the Medicare Part D benefit - stand-alone drug plans and Medicare Advantage drug plans - are increasingly are competing on uneven terms, in part because the payment system

Read full story

pharminent June 11, 2026 (Last updated: June 19, 2026)

KFF Medicare

The private plans that offer the Medicare Part D benefit – stand-alone drug plans and Medicare Advantage drug plans – are increasingly are competing on uneven terms, in part because the payment system

Read full story

Post navigation

Previous: Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026
Next: China’s NMPA approves Akeso’s gumokimab for plaque psoriasis

Related Stories

  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

pharminent September 1, 2026
  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.